Description
The concept of smart drug delivery vehicles involves designing and preparing a nanostructure (or microstructure) that can be loaded with a cargo. This can be a therapeutic drug, a contrast agent for imaging, or a nucleic acid for gene therapy. The nanocarrier serves to protect the cargo from degradation by enzymes in the body, to enhance the solubility of insoluble drugs, to extend the circulation half-life, and to enhance its penetration and accumulation at the target site. Importantly, smart nanocarriers can be designed to be responsive to a specific stimulus, so that the cargo is only released or activated when desired. In this volume we cover smart nanocarriers that respond to internal stimuli that are intrinsic to the target site. These stimuli are specific to the cell type, tissue or organ type, or to the disease state (cancer, infection, inflammation etc). pH-responsive nanostructures can be used for cargo release in acidic endosomal compartments, in the lower pH of tumors, and for specific oral delivery either to the stomach or intestine. Nanocarriers can be designed to be substrates of a wide-range of enzymes that are over-expressed at disease sites. Oxidation and reduction reactions can be taken advantage of in smart nanocarriers by judicious molecular design. Likewise, nanocarriers can be designed to respond to a range of specific biomolecules that may occur at the target site. In this volume we also cover dual and multi-responsive systems that combine stimuli that could be either internal or external.
About the Author
Karimi, Mahdi: - Mahdi Karimi received his BSc degree in Medical Laboratory Science from the Iran University of Medical Science (IUMS), in 2005. In 2008, he achieved the MSc degree in Medical Biotechnology from Tabriz University of Medical Science and joined the Tarbiat Modares University as a PhD student in the nanobiotechnology field and completed his research in 2013. During his research, in 2012, he affiliated with the laboratory of Professor Michael Hamblin in the Wellman Center for Photomedicine at Massachusetts General Hospital and Harvard Medical School as a researcher visitor, where he contributed to the design and construction of new smart nanoparticles for drug/gene delivery. On finishing the study, he joined, as Assistant Professor, the Department of Medical Nanotechnology at IUMS. His current research interests include smart nanoparticles' design in drug/gene delivery and microfluidic systems. He has established a scientific collaboration between his lab and Professor Michael Hamblin's lab to design new classes of smart nanovehicles in drug/gene delivery systems.
